| Synonyms: | |
| Status: | Approved (1985) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| ATC: | N06AX12 |
| UNII: | 01ZG3TPX31 |
| InChI Key | SNPPWIUOZRMYNY-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C13H18ClNO |
| Molecular Weight | 239.75 |
| AlogP | 3.3 |
| Hydrogen Bond Acceptor | 2.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 29.1 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 16.0 |
| Primary Target | |
|---|---|
| DAT | |
| NET |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor alpha subunit
|
- | 12-12000 | - | - | - | |
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor beta subunit
|
- | 12-12000 | - | - | - | |
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor delta subunit
|
- | 8-7900 | - | - | - | |
|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor gamma subunit
|
- | 8-7900 | - | - | - | |
|
Membrane receptor
|
- | 1800 | - | - | - | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC06 neurotransmitter transporter family
|
- | 550-2900 | - | 441-871 | 62 | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 7-109 |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Depressive Disorder | 4 | D003866 | ClinicalTrials |
| Depressive Disorder | 4 | D003866 | ClinicalTrials |
| Anxiety | 3 | D001007 | ClinicalTrials |
| Dementia | 3 | D003704 | ClinicalTrials |
| Depressive Disorder, Major | 3 | D003865 | ClinicalTrials |
| Schizophrenia | 3 | D012559 | ClinicalTrials |
| Tobacco Use Disorder | 3 | D014029 | ClinicalTrials |
| Attention Deficit Disorder with Hyperactivity | 3 | D001289 | ClinicalTrials |
| Smoking Cessation | 3 | D016540 | ClinicalTrials |
| Obesity | 3 | D009765 | ClinicalTrials |
| Huntington Disease | 2 | D006816 | ClinicalTrials |
| Crohn Disease | 2 | D003424 | ClinicalTrials |
| Amphetamine-Related Disorders | 2 | D019969 | ClinicalTrials |
| Marijuana Abuse | 2 | D002189 | ClinicalTrials |
| Substance-Related Disorders | 2 | D019966 | ClinicalTrials |
| Alcoholism | 2 | D000437 | ClinicalTrials |
| Cocaine-Related Disorders | 2 | D019970 | ClinicalTrials |
| Substance-Related Disorders | 2 | D019966 | ClinicalTrials |
| Restless Legs Syndrome | 2 | D012148 | ClinicalTrials |
| Mitochondrial Diseases | 1 | D028361 | ClinicalTrials |
| Alzheimer Disease | 1 | D000544 | ClinicalTrials |
| Bipolar Disorder | 1 | D001714 | ClinicalTrials |
| Neoplasms | 1 | D009369 | ClinicalTrials |
| Diabetes Mellitus, Type 2 | 1 | D003924 | ClinicalTrials |
| Carcinoma, Non-Small-Cell Lung | 1 | D002289 | ClinicalTrials |
| Sexual Dysfunction, Physiological | 1 | D012735 | ClinicalTrials |
| Head and Neck Neoplasms | 1 | D006258 | ClinicalTrials |
| Melanoma | 1 | D008545 | ClinicalTrials |
| Prostatic Neoplasms, Castration-Resistant | 1 | D064129 | ClinicalTrials |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | D015451 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 34911-55-2 |
| ChEBI | 3219 |
| ChEMBL | CHEMBL894 |
| DrugBank | DB01156 |
| DrugCentral | 435 |
| EPA CompTox | DTXSID7022706 |
| FDA SRS | 01ZG3TPX31 |
| Human Metabolome Database | HMDB0001510 |
| Guide to Pharmacology | 7135 |
| KEGG | C06860 |
| PharmGKB | PA448687 |
| PubChem | 444 |
| SureChEMBL | SCHEMBL38777 |